干扰素β1a对比干扰素β1b及常规方案治疗中重度COVID-19成年患者的随机对照试验方案结构化摘要
本研究为单中心、开放标签、随机对照平行组试验,计划纳入60例RT-PCR确诊的COVID-19中重度患者,随机分为三组:干扰素β1a组、干扰素β1b组和对照组,每组20例,主要结局为临床改善时间。
要点
- 主要结局为7分类序贯量表改善2分或出院的时间。
- 纳入标准包括SPO2≤93%或呼吸频率≥24次/分。
- 三组均接受羟氯喹和洛匹那韦/利托那韦基础治疗。
核心结论
- 该方案旨在评估干扰素β1a对比干扰素β1b及常规治疗对中重度COVID-19成年患者的有效性。
研究设计与样本
- 单中心、开放标签、随机对照平行组临床试验,在伊朗Shahid Beheshti医科大学Loghman Hakim医学教育中心进行。
- 计划纳入60例RT-PCR确诊的COVID-19患者,随机分为三组,每组20例,比例为1:1:1。
- 采用区组随机化(每区组3或6例),使用R软件生成序列,密封不透光信封分配隐藏。
主要发现
- 招募已于2020年4月9日至4月14日完成,尚待最终随访数据收集。
关键数值与推荐
- 纳入标准:年龄≥18岁,且SPO2≤93%或呼吸频率≥24次/分,同时至少具备以下一项:无接触红外额温≥37.8℃、咳嗽、咳痰、流涕、肌痛、头痛或乏力,症状出现时间≤14天。
- 排除标准包括:心脏问题(QT或PR间期延长、二度或三度心脏传导阻滞、心律失常包括尖端扭转型室速)、与羟氯喹+洛匹那韦/利托那韦或干扰素β1a/β1b有潜在相互作用的药物使用、妊娠或哺乳期、过去5年酒精或药物成瘾史、ALT/AST>5倍正常上限、拒绝参与。
- 主要结局:7分类序贯量表(WHO推荐)改善2分或出院的时间,以先发生者为准。
- 次要结局:随机化至研究最后一天的死亡率、SpO2改善(脉冲血氧测定法)、住院时长、新发机械通气使用率。
临床怎么用
- 该方案为COVID-19中重度患者提供了干扰素β1a和β1b联合基础治疗的随机对照研究框架,结果可能指导临床用药选择。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(60例),可能影响统计效能。
- 单中心研究,结果外推受限。
- 次要结局仍在完善中,方案尚未最终确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We will investigate the effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen in COVID-19 in patients that have tested positive and are moderately to severely ill. TRIAL DESIGN: This is a single center, open label, randomized, controlled, parallel group, clinical trial that will be conducted at Loghman Hakim Medical Education Center in conjunction with Shahid Beheshti University of Medical Sciences. PARTICIPANTS: Sixty COVID-19 confirmed cases (using the RT-PCR test) will be enrolled in the trial between April 9th to April 14th 2020. Patients will be randomly assigned to the intervention groups or the control group with the following eligibility criteria: ≥ 18 years of age AND (oxygen saturation (SPO2) ≤ 93% OR respiratory rate ≥ 24) AND at least one of the following: Contactless infrared forehead thermometer temperature of ≥37.8, cough, sputum production, nasal discharge, myalgia, headache or fatigue on admission, and time of onset of the symptoms should be acute (Days ≤ 14). Although Hydroxychloroquine will be administered in a single dose, patients with heart problems (prolonged QT or PR intervals, second- or third-degree heart block, and arrhythmias including torsade de pointes) will be excluded. Other exclusion criteria include using drugs with potential interaction with Hydroxychloroquine + Lopinavir/Ritonavir, Interferon-β 1a, Interferon-β 1b, pregnant or lactating women, history of alcohol or drug addiction in the past 5 years, blood ALT/AST levels > 5 times the upper limit of normal on laboratory results and refusal to participate. This study will be undertaken at the Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services. INTERVENTION AND COMPARATOR: COVID-19 confirmed patients will be randomly assigned to one of three groups, with 20 patients in each. The first group (Arm 1) will receive Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-β 1a (Recigen), the second group (Arm 2) will be administered Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon-β 1b (Ziferon), and the control group (Arm 3) will be treated by Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra). MAIN OUTCOMES: Time to clinical improvement is our primary outcome measure. This is an improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever comes first. Secondary outcomes include mortality from the date of randomization until the last day of the study which will be the day all of the patients have had at least one of the following outcomes: 1) Improvement of two points on a seven-category ordinal scale. 2) Discharge from the hospital 3) Death. If any patient dies, we have reached an important secondary outcome. SpO2 Improvement between the last and first day of hospitalization, using pulse-oximetry. Duration of hospitalization from date of randomization until the date of hospital discharge or date of death from any cause, whichever comes first. Incidence of new mechanical ventilation uses from date of randomization until the last day of the study. Please note that we are trying to add further secondary outcomes and this section of the protocol is still evolving. Statistical analysis will be performed by R version 3.6.1 software. We will use Kaplan-Meier to analyze the time to clinical improvement (compared with a log-rank test). Hazard ratios with 95% confidence intervals will be calculated using the Cox proportional-hazards model in crude and adjusted analysis. RANDOMIZATION: Eligible patients will be randomly assigned in a 1:1:1 ratio to receive either Interferon Beta 1a, Interferon Beta 1b or standard care only. Patients will be randomly allocated to three therapeutic arms using permuted, block-randomization to balance the number of patients allocated to each group. The permuted block (three or six patients per block) randomization sequence will be generated, using Package 'randomizeR' in R software version 3.6.1. and placed in individual sealed and opaque envelopes by the statistician. The investigator will enroll the patients and only then open envelopes to assign patients to the different treatment groups. This method of allocation concealment will result in minimum selection and confounding biases. BLINDING (MASKING): The present research is open-label (no masking) of patients and health care professionals who are undertaking outcome assessment of the primary outcome - time to clinical improvement. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): Of the 60 patients who underwent randomization, 20 patients were assigned to receive Interferon beta-1a, 20 patients were assigned to receive Interferon beta 1b plus standard care and the rest of patients were assigned to receive the standard care alone. TRIAL STATUS: Protocol version 1.2.1. Recruitment is finished, the start date of recruitment was on 9th April 2020 and the end date was on 14th April 2020. Last point of data collection will be the last day on which all of the 60 participants have had an outcome of clinical improvement or death, completing the study's follow-up time window. TRIAL REGISTRATION: This study was registered with National Institutes of Health Clinical trials (www.clinicaltrials.gov; identification number NCT04343768, registered April 8, 2020 and first available online April 13, 2020). FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Irvani SSN, Golmohammadi M, Pourhoseingholi MA, et al. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32493468. doi:10.1186/s13063-020-04382-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。